Literature DB >> 17242007

N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population.

Michael H Olsen1, Tine W Hansen, Marina K Christensen, Finn Gustafsson, Susanne Rasmussen, Kristian Wachtell, Hans Ibsen, Christian Torp-Pedersen, Per R Hildebrandt.   

Abstract

AIM: Serum N-terminal pro-brain natriuretic peptide (Nt-proBNP), high sensitivity (hs)-C-reactive protein, and urine albumin/creatinine ratio (UACR) are cardiovascular (CV) risk markers in the general population. The aim of this study was to determine whether they predicted CV events independently of established CV risk factors and whether they did so in an additive fashion. METHODS AND
RESULTS: In a population-based sample of 2656 individuals, 41, 51, 61, and 71 years old, we measured UACR, serum Nt-proBNP, hs-C-reactive protein, insulin, lipids and plasma glucose, clinic blood pressures, body composition, left ventricular (LV) mass index, and ejection fraction (EF) by echocardiography and pulse wave velocity. During the following 9.4 years, the combined CV endpoint (CEP) of CV death (136), non-fatal stroke, or non-fatal myocardial infarction occurred in 219 subjects. After adjustment for established CV risk factors using Cox-regression analyses, CEP and CV death were predicted by log(Nt-proBNP)/SD [hazard ratio (HR) = 1.58 and HR = 1.80, both P < 0.001] and by log(UACR)/SD (HR = 1.44 and HR = 1.52, both P < 0.001) in an additive fashion, but not by log(hs-C-reactive protein)/SD (HR = 1.17, P = 0.06 and HR = 1.13, NS). CV risk functions were constructed on the basis of Cox-regression analyses. Inclusion of Nt-proBNP and UACR did not increase the area under the receiver-operating characteristic plots.
CONCLUSION: Serum Nt-proBNP and UACR, but not hs-C-reactive protein, predicted CV events after adjustment for established CV risk factors including LV EF and relative wall thickness. However, more studies in relevant subgroups are needed before Nt-proBNP and UACR can be recommended for risk prediction in the general population to select subjects for primary prevention.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242007     DOI: 10.1093/eurheartj/ehl448

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  40 in total

1.  Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes.

Authors:  Conall M O'Seaghdha; Shih-Jen Hwang; Martin G Larson; James B Meigs; Ramachandran S Vasan; Caroline S Fox
Journal:  J Am Soc Nephrol       Date:  2013-08-29       Impact factor: 10.121

2.  The association of plasma lactate with incident cardiovascular outcomes: the ARIC Study.

Authors:  Kunihiro Matsushita; Emma K Williams; Morgana L Mongraw-Chaffin; Josef Coresh; Maria Ines Schmidt; Frederick L Brancati; Ron C Hoogeveen; Christie M Ballantyne; J Hunter Young
Journal:  Am J Epidemiol       Date:  2013-06-30       Impact factor: 4.897

Review 3.  Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure.

Authors:  Claire Sweeney; Fiona Ryan; Mark Ledwidge; Cristin Ryan; Ken McDonald; Chris Watson; Rebabonye B Pharithi; Joe Gallagher
Journal:  Cochrane Database Syst Rev       Date:  2019-10-15

4.  Prognostic value of NT-pro-BNP and hs-CRP for risk stratification in primary care: results from the population-based DETECT study.

Authors:  David M Leistner; Jens Klotsche; Lars Pieper; Sylvia Palm; Günter K Stalla; Hendrik Lehnert; Sigmund Silber; Winfried März; Hans-Ulrich Wittchen; Andreas M Zeiher
Journal:  Clin Res Cardiol       Date:  2013-01-04       Impact factor: 5.460

5.  Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts.

Authors:  D S Cross; C A McCarty; E Hytopoulos; M Beggs; N Nolan; D S Harrington; T Hastie; R Tibshirani; R P Tracy; B M Psaty; R McClelland; P S Tsao; T Quertermous
Journal:  Curr Med Res Opin       Date:  2012-11       Impact factor: 2.580

Review 6.  Biomarkers of atherosclerosis: clinical applications.

Authors:  Todd M Brown; Vera Bittner
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

7.  Troponin T, B-type natriuretic peptide, C-reactive protein, and cause-specific mortality.

Authors:  Oludamilola W Oluleye; Aaron R Folsom; Vijay Nambi; Pamela L Lutsey; Christie M Ballantyne
Journal:  Ann Epidemiol       Date:  2012-12-08       Impact factor: 3.797

8.  Plasma NT-proBNP as predictor of change in functional status, cardiovascular morbidity and mortality in the oldest old: the Leiden 85-plus study.

Authors:  Petra G van Peet; Anton J M de Craen; Jacobijn Gussekloo; Wouter de Ruijter
Journal:  Age (Dordr)       Date:  2014-05-08

9.  Natriuretic Peptides and Assessment of Cardiovascular Disease Risk in Asymptomatic Persons.

Authors:  Lori B Daniels
Journal:  Curr Cardiovasc Risk Rep       Date:  2010-02-17

10.  Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study.

Authors:  Martin J Landray; Jonathan R Emberson; Lisa Blackwell; Tanaji Dasgupta; Rosita Zakeri; Matthew D Morgan; Charlie J Ferro; Susan Vickery; Puja Ayrton; Devaki Nair; R Neil Dalton; Edmund J Lamb; Colin Baigent; Jonathan N Townend; David C Wheeler
Journal:  Am J Kidney Dis       Date:  2010-10-30       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.